A trial of the PSMA XPAT molecule (JANX007) produced PSA50 responses in 5/6 patients dosed at 0.2 mg or above, but no partial response with doses up to 3 mg (NCT05519449); the EGFR XPAT molecule (JANX008) produced 1 partial response (PR) in an NSCLC patient at a 0.15 mg dose, but no additional response in 10 other patients dosed as high as 1.25 mg (NCT05783622); the EGFR Probody (CX-904) generated 2/6 PRs in pancreatic cancer patients, but no objective response in 20 other patients in the trial, across multiple indications and at similar or higher doses (NCT05387265). Here, EGFR is linked to familial pancreatic carcinoma.